The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The utility of bi-weekly eribulin therapy for metastatic breast cancer: A Japanese multicenter phase II study (JUST-STUDY).
 
Tetsuhiro Yoshinami
No Relationships to Disclose
 
Norikazu Masuda
Honoraria - AstraZeneca; Chugai Pharma; Eisai; GlaxoSmithKline; Kyowa Hakko Kirin; Novartis; Sanofi
Research Funding - AstraZeneca; Chugai Pharma; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
 
Takahiro Nakayama
No Relationships to Disclose
 
Fumikata Hara
Research Funding - Chugai Pharma; Eisai
 
Yasuaki Sagara
No Relationships to Disclose
 
Hidetoshi Kawaguchi
No Relationships to Disclose
 
Ken-ichi Watanabe
No Relationships to Disclose
 
Masako Sato
No Relationships to Disclose
 
Kenjiro Aogi
Honoraria - AstraZeneca; Becton Dickinson; Chugai Pharma; Daiichi Sankyo; Eisai; Nihon Medi-Physics; Ono Pharmaceutical; Otsuka; Sanofi; Taiho Pharmaceutical
 
Kenji Higaki
No Relationships to Disclose
 
Takashi Morimoto
No Relationships to Disclose
 
Yasushi Shigeoka
No Relationships to Disclose
 
Shinya Tokunaga
No Relationships to Disclose
 
Hirotaka Morishima
No Relationships to Disclose
 
Yasuhiro Yanagita
No Relationships to Disclose
 
Junji Tsurutani
No Relationships to Disclose
 
Shinichi Baba
No Relationships to Disclose
 
Kazuhisa Katayama
No Relationships to Disclose
 
Satoshi Morita
Honoraria - Eisai
Research Funding - Eisai (Inst)
 
Shoichiro Ohtani
No Relationships to Disclose